利塞膦酸钠干预绝经后妇女骨量的研究(附223例报告)  

The effect of risedronate on bone mineral density in postmenopausal women

作　　者：林华[1] 包丽华[2] 李滨 刘树琴[4] 于浩[5] 

机构地区：[1]南京大学医学院附属鼓楼医院骨病中心,南京210008 [2]江苏省人民医院 [3]芜湖华信生物药业有限公司 [4]安徽医科大学第一附属医院 [5]南京医科大学

出　　处：《中国骨质疏松杂志》2007年第10期727-732,共6页Chinese Journal of Osteoporosis

基　　金：南京市医学科技重点发展基金资助项目(ZKG9913)

摘　　要：目的评价口服利塞膦酸钠对绝经后妇女骨量变化的干预作用。方法223名绝经后妇女随机分为两组:A组(利塞膦酸钠,5mg/d,口服)和B组(安慰剂,每天1片),所有患者每天补充钙剂500mg和维生素D200IU,治疗1年。腰椎和髋部(包括股骨颈、转子间和Ward三角)骨量双能X骨密度测量分别于治疗前、治疗6个月和12个月时进行。结果所有患者为骨量减少,治疗前患者的一般情况和骨量两组间无差异。治疗结束后,利塞膦酸钠组患者腰椎和股骨颈的骨量较安慰剂对照组明显上升(P<0.05)。结论口服利塞膦酸钠可显著提高腰椎和髋部骨量,有效防治绝经后骨质疏松。Objective The purpose of the present study was to evaluate the therapeutic effect on bone mineral density （BMD） of risedronate in postmenopausal osteoporotic women. Methods 223 postmenopausal patients were randomly divided into two administration groups： group A （risedronate, 5 mg/day, daily） and group B （placebo, daily）. They received either risedronate （5 mg/day, orally） or placebo for up to 1 year. All subjects received calcium and vitamin D supplementation. The BMD of the lumbar spine （ L2 - L4 ） and hip （ neck, trochanter and Ward＇s） were measured by dual-energy X-ray absorptiometry at baseline, 6 months, and 12 months after treatment. The patients were followed up every 3 mo for 12 mo, BMD measurements were taken at baseline, 6mo and at the end of the study. Results At baseline, both risedronate and placebo groups patients had bone mineral density （BMD） 1.0 SD or more below the young adult women mean. There were no significant differences in age, body mass index, BMD at baseline between the two groups. At the end of the study, there were statistically significant increases in BMD in group A at two sites at lumbar spine and neck of hip （ P 〈 0. 05）. Conclusions Risedronate apparently has a statistically significant therapeutic effect on bone mineral density （BMD） on lumbar and hip for prevention and treatment of postmenopausal osteoporosis.

关 键 词：绝经后骨质疏松 利塞膦酸钠 骨密度 

分 类 号：R681.05[医药卫生—骨科学]